Farxiga

Farxiga · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 18, 2026

42 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (54)

Oct 1, 2041patentUS 12213988*PED
Oct 1, 2041patentUS 12409186*PED
Apr 1, 2041method-of-use (U-4140)US 12213988
Apr 1, 2041method-of-use (U-4140)US 12409186
Sep 9, 2040patentUS 10973836*PED
Sep 9, 2040patentUS 11903955*PED
Mar 9, 2040method-of-use (U-3127)US 10973836
Mar 9, 2040method-of-use (U-3825)US 11903955
Jan 18, 2040patentUS 11826376*PED
Jan 18, 2040patentUS 12472194*PED
Jul 18, 2039method-of-use (U-3766)US 11826376
Jul 18, 2039method-of-use (U-4346)US 12472194
Nov 26, 2030patentUS 8685934*PED4.4y
Nov 26, 2030patentUS 8685934*PED4.4y
Jul 18, 2030patentUS 8721615*PED4.0y
Jul 18, 2030patentUS 8721615*PED4.0y
Jun 16, 2030patentUS 7919598*PED3.9y
Jun 16, 2030patentUS 7919598*PED3.9y
May 26, 2030method-of-use (U-1522)US 86859343.9y
May 26, 2030method-of-use (U-1522)US 86859343.9y
Dec 16, 2029compositionUS 79195983.4y
Dec 16, 2029compositionUS 79195983.4y
Feb 19, 2029patentUS 7851502*PED2.6y
Feb 19, 2029patentUS 7851502*PED2.6y
Sep 21, 2028patentUS 8221786*PED2.2y
Sep 21, 2028patentUS 8221786*PED2.2y
Sep 21, 2028patentUS 8361972*PED2.2y
Sep 21, 2028patentUS 8361972*PED2.2y
Sep 21, 2028patentUS 8716251*PED2.2y
Sep 21, 2028patentUS 8716251*PED2.2y
Aug 19, 2028formulationUS 78515022.1y
Aug 19, 2028formulationUS 78515022.1y
Mar 21, 2028formulationUS 82217861.7y
Mar 21, 2028formulationUS 82217861.7y
Mar 21, 2028method-of-use (U-493)US 83619721.7y
Mar 21, 2028method-of-use (U-493)US 83619721.7y
Mar 21, 2028formulationUS 87162511.7y
Mar 21, 2028formulationUS 87162511.7y
Dec 20, 2027patentUS 8501698*PED1.5y
Dec 20, 2027patentUS 8501698*PED1.5y
Jun 20, 2027formulationUS 8501698348d
Jun 20, 2027formulationUS 8501698348d
Feb 18, 2027patentUS 8329648*PED226d
Feb 18, 2027patentUS 8329648*PED226d
Feb 18, 2027patentUS 8906851*PED226d
Feb 18, 2027patentUS 8906851*PED226d
Aug 18, 2026method-of-use (U-2213)US 832964842d
Aug 18, 2026method-of-use (U-2212)US 832964842d
Aug 18, 2026method-of-use (U-2139)US 890685142d
Aug 18, 2026method-of-use (U-2139)US 890685142d
Apr 4, 2026patentUS 6515117*PED
Apr 4, 2026patentUS 6515117*PED
Oct 4, 2025compositionUS 6515117
Oct 4, 2025compositionUS 6515117

FDA exclusivities (8)

Dec 12, 2027PEDPediatric (6mo bonus)1.4y
Dec 12, 2027PEDPediatric (6mo bonus)1.4y
Jun 12, 2027NPPNew Product (3y)340d
Jun 12, 2027NPPNew Product (3y)340d
Nov 8, 2026PEDPediatric (6mo bonus)124d
Nov 8, 2026PEDPediatric (6mo bonus)124d

dapagliflozin propanediol

indications

targets

all catalysts(0)

News(0)

comments(0)

Report a data issue

Patent cliff

patents (54)

FDA exclusivities (8)

Trials studying dapagliflozin propanediol